Study on the Effects of Repetitive Transcranial Magnetic Stimulation on Frontal Cortex Activity and Neurological Recovery in Patients with Traumatic Brain Injury

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600118462

Enrollment

Unknown

Registered

2026-02-05

Start date

2026-03-01

Completion date

Unknown

Last updated

2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic Brain Injury (TBI) with persistent executive dysfunction

Interventions

Active rTMS Group:High-frequency repetitive transcranial magnetic stimulation (rTMS) over the left dorsolateral prefrontal cortex (DLPFC) + standard multidisciplinary rehabilitation

Sham Control Group: Sham rTMS stimulation + standard multidisciplinary rehabilitation

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-70 years old; 2. 3-12 months after the occurrence of closed brain trauma; 3. Presence of persistent executive dysfunction with a score of <=14 on the Frontal Lobe Assessment Scale (FAB) and/or an Executive Index of <=4 on the Montreal Cognitive Assessment (MoCA); 4. Stable drug treatment regimen in the past 4 weeks (no addition, adjustment or discontinuation of related drugs); 5. Meet the conditions for magnetic resonance imaging (MRI) examination (no contraindications to MRI examination).

Exclusion criteria

Exclusion criteria: 1. History of epilepsy unrelated to traumatic brain injury within the past 1.6 months; 2. Skull defect in the frontal lobe target area; 3. Presence of implants in the body that are contraindicated for MRI (such as a pacemaker, metal foreign bodies, etc.); 4. Severe aphasia making it impossible to complete study-related tests and assessments; 5. Active major depression requiring adjustment of psychiatric medication treatment; 6. Meets the contraindications for rTMS treatment as defined by the International Federation of Clinical Neurophysiology (IFCN).

Design outcomes

Primary

Measure	Time frame
Frontal Assessment Battery (FAB) Score;	—

Secondary

Measure	Time frame
MoCA Executive Index;Glasgow Outcome Scale–Extended (GOSE) Score;Trail-Making Test A/B (TMT-A/B);Patient-Reported Cognitive Difficulties Scale Score;TMS-EEG Evoked Potentials (N100/P200 Amplitude);fNIRS Oxyhemoglobin (HbO);rs-fMRI DLPFC–Frontoparietal Network (FPN) Connectivity;	—

Countries

China

Contacts

Public ContactHu Nan

Affiliated Cancer Hospital of Tianjin Medical University

hunanmazui@163.com+86 135 0217 3859

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026